European Free-to-Air TV Platforms Endorse Intertrust ExpressPlay XCA for Broadcast Content Protection
13.9.2018 15:00:00 EEST | Business Wire | Press release
Free-to-air TV platforms Freesat and Tivù have today endorsed Intertrust’s ExpressPlay XCA™ conditional access system (CAS) at IBC.
As the inventor of Digital Rights Management (DRM) technology, Intertrust introduced ExpressPlay XCA (XCA), a modern CAS that is based on their popular open standard Marlin technology, which was originally founded by Intertrust, Panasonic, Philips, Sony, and Samsung. ExpressPlay XCA leverages hardware security in smart TV and set-top box chipsets to provide world-class content security and full CAS capabilities – including head-end integration at a fraction of the cost of a legacy CAS.
“For years, TV operators have had to manage a tricky balance between set-top box manufacturers and CAS providers to deliver premium TV, often leaving themselves at the mercy of CAS vendors. Meanwhile broadband TV providers use easy-to-integrate DRM with far less overhead,” said Talal G. Shamoon, Intertrust’s chief executive officer. “With today’s TV chipsets, smart TVs and set-top boxes, we can remove legacy problems with our Marlin DRM-based XCA while reducing costs and time-to-market, and increasing choice.”
With increasing competition from the Internet, traditional TV operators are embracing economies of scale provided by modern technology. In response to smart TV manufacturers readily integrating DRM systems into their OTT stack, Intertrust created XCA to provide broadcasters with a simple way to reduce their costs.
“As Freesat expands its connected product range, we sought a cost efficient, open alternative to traditional CAS,” said Andy Carr Director of CE @ Freesat. “XCA provides us with industry approved content security across a broad range of devices. As our service continues to grow, Intertrust becomes a key partner for us protecting the best possible high-value entertainment experience for our customers.”
To protect and manage content, XCA technology is used in TV platforms across Europe, India, China, Japan, and the United States. Its advanced DRM software engine efficiently protects broadcast streams, resulting in a future proof, open technology that is flexible and cost effective.
“Our viewers are the most important element in the equation,” said Alberto Sigismondi, Tivù chief executive officer. “With XCA, we could provide our viewers with a range of content choice across traditional TV platforms and set-top boxes, but also bridge the gap between the interests of Italy’s broadcasters.”
Intertrust also announced at IBC that Vestel, Europe’s second largest TV manufacturer will incorporate XCA into their smart TVs. Vestel joins a growing community of device makers who support Marlin-based technologies around the world.
About Intertrust
Intertrust provides trusted computing products and services to leading global corporations – from mobile, CE and IoT manufacturers, to service providers, and enterprise software platform companies. These products include the world’s leading digital rights management (DRM), software tamper resistance, and technologies to enable private data exchanges for various verticals including energy, entertainment, retail/marketing, automotive, fintech, and IoT.
Founded in 1990, Intertrust is headquartered in Silicon Valley with regional offices in London, Tokyo, Mumbai, Bangalore, Hyderabad, Beijing, Seoul, Riga, and Tallinn. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust, and privacy management components of operating systems, trusted mobile code and networked operating environments, web services, and cloud computing.
Additional information is available at intertrust.com, or follow us on Twitter or LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005407/en/
Contact information
Intertrust Technologies Corporation
Nishtha Sharma, +91 981-932-6284
nishthas@intertrust.com
or
Actual
Agency
Brian Regan, +1 908-399-7161
brian.regan@actual.agency
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
LogicMonitor and Deutsche Telekom Expand Partnership Across Europe18.5.2026 10:00:00 EEST | Press release
LogicMonitor®, the AI-first platform for Autonomous IT, today announced the expanded availability of its platform within Deutsche Telekom’s managed services portfolio across selected European markets, including DACH, Benelux, and the Nordics. The expansion builds on operational use of LogicMonitor in the United Kingdom since 2023, where it has supported Deutsche Telekom’s service teams in improving visibility across network, cloud, and hybrid infrastructure environments. Experience gained from these deployments is now informing broader service enablement across additional European markets. As enterprise IT environments grow more complex, organisations require more than visibility—they need predictive resilience. Through defined use cases, LogicMonitor complements Deutsche Telekom’s existing service management, monitoring, and security tooling, helping teams anticipate, detect, and resolve issues before they impact business operations. In the United Kingdom, the partnership has delivere
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer18.5.2026 09:00:00 EEST | Press release
VahatiCor, Inc., a medtech company developing interventional therapies for Coronary Microvascular Dysfunction (CMD), announced today the appointment of Harry D. Rowland, Ph.D., as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517830314/en/ VahatiCor CEO, Harry D. Rowland, Ph.D. Rowland previously served as Chief Executive Officer and President of Endotronix, where he led the development and commercialization of the Cordella™ Pulmonary Artery Sensor and Heart Failure System. Under his leadership, Endotronix raised over $150 million and grew to more than 150 employees. He also oversaw the PROACTIVE-HF pivotal trial from execution through FDA premarket approval and commercial launch. Following its acquisition by Edwards Lifesciences in 2024, Rowland stayed on to support key CMS national coverage and CE Mark milestones. "Harry has led a medical company through this arc before. He took Endotronix from
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom